Skip to main content
main-content

Zeitschrift

Cancer Chemotherapy and Pharmacology

Cancer Chemotherapy and Pharmacology OnlineFirst articles

23.02.2018 | Short Communication

Ibrutinib brain distribution: a preclinical study

Ibrutinib (Imbruvica®, Janssen-Cilag, IBR) is an orally administered Bruton’s tyrosine kinase (BTK) inhibitor, which is highly active with durable single-agent activity indicated in chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia …

23.02.2018 | Original Article

Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro

The phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathway is involved in multiple processes including cell cycle regulation, survival, adhesion, motility and angiogenesis [ 1 …]. Since this pathway is frequently dysregulated in human cancers [

22.02.2018 | Original Article

Influence of gemcitabine chemotherapy on the microbiota of pancreatic cancer xenografted mice

Pancreatic ductal adenocarcinoma (PDAC) accounts for 85–95% of pancreatic cancers [ 1 , 2 ], which represent the fourth lethal malignancy, with only less than 5% of patients reaching 5-year survival [ 3 ]. This poor outcome is attributable to lack …

21.02.2018 | Original Article

Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer

Crizotinib is a potent oral small-molecule inhibitor of anaplastic lymphoma kinase (ALK), mesenchymal epithelial transition factor/hepatocyte growth factor receptor (c-Met), recepteur d’origine nantais (RON), and c-Ros oncogene 1 (ROS1) receptor …

21.02.2018 | Original Article

Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors

Combining sorafenib and eribulin mesylate may provide synergistic antitumor activities with limited overlapping toxicities. This phase 1b, open-label, dose-escalation study evaluated safety, pharmacokinetics, maximum tolerated dose/recommended …

Aktuelle Ausgaben

Über diese Zeitschrift

Cancer Chemotherapy and Pharmacology addresses a wide range of pharmacologic and oncologic concerns on both experimental and clinical levels. The primary focus of this rapid publication medium is on new anticancer agents, their experimental screening, preclinical toxicology and pharmacology, single and combined drug administration modalities, and clinical phase I, II and III trials.

The journal publishes results recorded in the following areas: clinical toxicology, pharmacokinetics, pharmacodynamics, drug interactions, and indications for chemotherapy in cancer treatment strategy. Cancer Chemotherapy and Pharmacology is essential reading for pharmacologists and oncologists.

Weitere Informationen

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise